506 related articles for article (PubMed ID: 21269402)
1. A phase IV prospective evaluation of the safety and efficacy of extended release testosterone pellets for the treatment of male hypogonadism.
Kaminetsky JC; Moclair B; Hemani M; Sand M
J Sex Med; 2011 Apr; 8(4):1186-96. PubMed ID: 21269402
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of testosterone replacement gel for treating hypogonadism in men: Phase III open-label studies.
Belkoff L; Brock G; Carrara D; Neijber A; Ando M; Mitchel J
Andrologia; 2018 Feb; 50(1):. PubMed ID: 28295450
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics, Clinical Efficacy, Safety Profile, and Patient-Reported Outcomes in Patients Receiving Subcutaneous Testosterone Pellets 900 mg for Treatment of Symptoms Associated With Androgen Deficiency.
McMahon CG; Shusterman N; Cohen B
J Sex Med; 2017 Jul; 14(7):883-890. PubMed ID: 28673432
[TBL] [Abstract][Full Text] [Related]
4. The long-term efficacy and safety of a testosterone mucoadhesive buccal tablet in testosterone-deficient men.
Dinsmore WW; Wyllie MG
BJU Int; 2012 Jul; 110(2):162-9. PubMed ID: 22288877
[TBL] [Abstract][Full Text] [Related]
5. IPASS: a study on the tolerability and effectiveness of injectable testosterone undecanoate for the treatment of male hypogonadism in a worldwide sample of 1,438 men.
Zitzmann M; Mattern A; Hanisch J; Gooren L; Jones H; Maggi M
J Sex Med; 2013 Feb; 10(2):579-88. PubMed ID: 22812645
[TBL] [Abstract][Full Text] [Related]
6. A multi-institutional observational study of testosterone levels after testosterone pellet (Testopel(®)) insertion.
McCullough AR; Khera M; Goldstein I; Hellstrom WJ; Morgentaler A; Levine LA
J Sex Med; 2012 Feb; 9(2):594-601. PubMed ID: 22240203
[TBL] [Abstract][Full Text] [Related]
7. Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men.
Arver S; Dobs AS; Meikle AW; Caramelli KE; Rajaram L; Sanders SW; Mazer NA
Clin Endocrinol (Oxf); 1997 Dec; 47(6):727-37. PubMed ID: 9497881
[TBL] [Abstract][Full Text] [Related]
8. Optimal diagnostic measures and thresholds for hypogonadism in men with HIV/AIDS: comparison between 2 transdermal testosterone replacement therapy gels.
Blick G
Postgrad Med; 2013 Mar; 125(2):30-9. PubMed ID: 23816769
[TBL] [Abstract][Full Text] [Related]
9. Testosterone release rate and duration of action of testosterone pellet implants.
Kelleher S; Howe C; Conway AJ; Handelsman DJ
Clin Endocrinol (Oxf); 2004 Apr; 60(4):420-8. PubMed ID: 15049955
[TBL] [Abstract][Full Text] [Related]
10. Prostate-specific antigen (PSA) concentrations in hypogonadal men during 6 years of transdermal testosterone treatment.
Raynaud JP; Gardette J; Rollet J; Legros JJ
BJU Int; 2013 May; 111(6):880-90. PubMed ID: 23294726
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic evaluation and dosing of subcutaneous testosterone pellets.
Pastuszak AW; Mittakanti H; Liu JS; Gomez L; Lipshultz LI; Khera M
J Androl; 2012; 33(5):927-37. PubMed ID: 22403285
[TBL] [Abstract][Full Text] [Related]
12. Outcomes with the "V" implantation technique vs. standard technique for testosterone pellet therapy.
Conners W; Flinn K; Morgentaler A
J Sex Med; 2011 Dec; 8(12):3465-70. PubMed ID: 21883944
[TBL] [Abstract][Full Text] [Related]
13. Testosterone undecanoate in the treatment of male hypogonadism.
Edelstein D; Basaria S
Expert Opin Pharmacother; 2010 Aug; 11(12):2095-106. PubMed ID: 20642374
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and pharmacodynamics of subcutaneous testosterone implants in hypogonadal men.
Jockenhövel F; Vogel E; Kreutzer M; Reinhardt W; Lederbogen S; Reinwein D
Clin Endocrinol (Oxf); 1996 Jul; 45(1):61-71. PubMed ID: 8796140
[TBL] [Abstract][Full Text] [Related]
15. Treatment of hypogonadal adolescent boys with long acting subcutaneous testosterone pellets.
Zacharin MR; Warne GL
Arch Dis Child; 1997 Jun; 76(6):495-9. PubMed ID: 9245845
[TBL] [Abstract][Full Text] [Related]
16. Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome.
Giltay EJ; Tishova YA; Mskhalaya GJ; Gooren LJ; Saad F; Kalinchenko SY
J Sex Med; 2010 Jul; 7(7):2572-82. PubMed ID: 20524974
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and pharmacodynamics of testosterone pellets in man.
Handelsman DJ; Conway AJ; Boylan LM
J Clin Endocrinol Metab; 1990 Jul; 71(1):216-22. PubMed ID: 2115044
[TBL] [Abstract][Full Text] [Related]
18. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
Coward RM; Simhan J; Carson CC
BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
[TBL] [Abstract][Full Text] [Related]
19. Retrospective investigation of testosterone undecanoate depot for the long-term treatment of male hypogonadism in clinical practice.
Conaglen HM; Paul RG; Yarndley T; Kamp J; Elston MS; Conaglen JV
J Sex Med; 2014 Feb; 11(2):574-82. PubMed ID: 24279472
[TBL] [Abstract][Full Text] [Related]
20. Testosterone replacement therapy does not promote priapism in hypogonadal men with sickle cell disease: 12-month safety report.
Morrison BF; Reid M; Madden W; Burnett AL
Andrology; 2013 Jul; 1(4):576-82. PubMed ID: 23606509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]